Follow The Filings

CRMD CorMedix

CorMedix earnings company data as of 4:48 AM ET 10/23

  • 0 of 1 EPS beats

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 11 Nov EPS — — —
Rev — — —
FY2026 Q2 13 Aug EPS 0.26 0.19 Miss -26.9%
Rev — $101.9M —

Insider trades

Open-market buys and sales by CRMD's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CRMD insider trades
  • $276K bought by 1 insider
  • $1.1M sold by 2 insiders outside a trading plan
  • $1.6M sold by 3 insiders under 10b5-1 plans
  1. Janet Dillione Director
    Planned sale
    $69K 10,000 shares at $6.88 21% of stake
    Traded Jan 21 Filed Jan 22
  2. Alan W Dunton Director
    Planned sale
    $260K 20,000 shares at $13.00 33% of stake
    Traded Dec 30, 2025 Filed Jan 2
  3. Joseph Todisco CEO
    Planned sale
    $360K 30,000 shares at $12.00 5.6% of stake
    Traded Dec 18, 2025 Filed Dec 19, 2025
  4. Janet Dillione Director
    Planned sale
    $408K 34,000 shares at $12.00 41% of stake
    Traded Dec 9, 2025 Filed Dec 11, 2025
  5. Steven W Lefkowitz Director
    Sale
    $475K 40,000 shares at $11.88 33% of stake
    Traded Dec 9, 2025 Filed Dec 10, 2025
  6. Janet Dillione Director
    Planned sale
    $467K 46,657 shares at $10.00 49% of stake
    Traded Dec 2, 2025 Filed Dec 4, 2025
  7. Janet Dillione Director
    Sale
    $262K 26,343 shares at $9.93 35% of stake
    Traded Nov 24, 2025 Filed Nov 26, 2025
  8. Janet Dillione Director
    Sale
    $343K 30,000 shares at $11.42 38% of stake
    Traded Nov 14, 2025 Filed Nov 18, 2025
  9. Myron Kaplan Director
    Buy
    $276K 25,000 shares at $11.02 +14% to stake
    Traded Oct 23, 2025 Filed Oct 27, 2025

Also filed in the last 12 months, not counted as buying or selling: 14 stock grants, 14 option exercises, and 12 share withholdings for taxes.

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
8-K 7.01,9.01
8-K 2.02,9.01
10-Q
8-K 8.01,9.01
8-K 8.01
8-K 4.01
8-K 5.07
SCHEDULE 13G/A —
SCHEDULE 13G/A —
8-K 7.01,9.01
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
DEF 14A PROXY STATEMENT
DEFA14A DEFINITIVE ADDITIONAL MATERIALS
8-K 7.01,9.01
SCHEDULE 13G/A —
8-K 7.01,9.01
8-K 2.02,9.01
10-K ANNUAL REPORT

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.